Diels-alder reaction for tumor pretargeting: In vivo chemistry can boost tumor radiation dose compared with directly labeled antibody

Journal of Nuclear Medicine

Volumn 54, Issue 11, 2013, Pages 1989-1995

  Rossin, Raffaella ^a   Läppchen, Tilman ^a   Van Den Bosch, Sandra M ^a   Laforest, Richard ^b   Robillard, Marc S ^a  

^a PHILIPS RESEARCH LABORATORIES   (Netherlands)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clearing agent; Diels Alder; Dosimetry; Pretargeting

Indexed keywords

IODINE MONOCLONAL ANTIBODY CC49 CYCLOOCTENE I 125; LUTETIUM MONOCLONAL ANTIBODY CC49 TETRAXETAN LU 177; LUTETIUM TETRAZINE LU 177; MONOCLONAL ANTIBODY CC49; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CYCLOOCTANE; CYCLOOCTANE DERIVATIVE; MONOCLONAL ANTIBODY; SINGLE HETEROCYCLIC RINGS; LUTETIUM 177;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CHEMICAL PARAMETERS; COLON CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; CT SPECT SCANNER; DIELS ALDER REACTION; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TUMOR LEVEL; FEMALE; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MEAN RESIDENCE TIME; MOLECULAR STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RADIATION DOSE; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; RADIOISOTOPE DECAY; RADIOLOGICAL PROCEDURES; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR PRETARGETING; TUMOR TO BLOOD RATIO; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; CYCLOADDITION; KINETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES; RADIOGRAPHY; RADIOMETRY; SCINTISCANNING; CLEARING AGENT; DIELS-ALDER; METHODOLOGY; NEOPLASM; PRETARGETING;

ANIMALS; ANTIBODIES, MONOCLONAL; CYCLOADDITION REACTION; CYCLOOCTANES; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; ISOTOPE LABELING; KINETICS; MICE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; NEOPLASMS; RADIATION DOSAGE; RADIOMETRY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

177LU; CLEARING AGENT; DIELS-ALDER; DOSIMETRY; PRETARGETING;

EID: 84891690168     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.123745     Document Type: Article

References (29)

1. Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007;34:757-778.
2. Sharkey RM, Goldenberg DM. Pretargeted radioimmunotherapy of cancer. In: Reilly RM, ed. Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer. Hoboken, NJ: John Wiley and Sons; 2010:241-287.
3. Aweda TA, Beck HE, Wu AM, Wei LH, Weber WA, Meares CF. Rates and equilibria for probe capture by an antibody with infinite affinity. Bioconjug Chem. 2010;21:784-791.
4. Kuijpers WHA, Kaspersen FM, Veeneman GH, Van Boeckel CAA, Bos ES. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer. Bioconjug Chem. 1993;4:94-102.
5. Liu G, Mang'era K, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using 99mTc-labeled morpholino, a DNA analog. J Nucl Med. 2002;43:384-391.
6. Sletten EM, Bertozzi CR. Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. Angew Chem Int Ed Engl. 2009;48:6974-6998.
7. Blackman ML, Royzen M, Fox JM. Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity. J Am Chem Soc. 2008;130: 13518-13519.
8. Rossin R, Renart Verkerk P, van den Bosch S, et al. In vivo chemistry for pretargeted tumor imaging in live mice. Angew Chem Int Ed Engl. 2010;49: 3375-3378.
9. Devaraj NK, Thurber GM, Keliher EJ, Marinelli B, Weissleder R. Reactive polymer enables efficient in vivo bioorthogonal chemistry. Proc Natl Acad Sci USA. 2012;109:4762-4767.
10. Zeglis BM, Sevak KK, Reiner T, et al. A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. J Nucl Med. 2013;54:1389-1396.
11. 90Y-DOTAbiotin. J Nucl Med. 2000;41:131-140.
12. Rossin R, Van den Bosch SM, ten Hoeve W, et al. Highly reactive transcyclooctene tags with improved stability for Diels-Alder chemistry in living systems. Bioconjug Chem. 2013;24:1210-1217.
13. Guide for the Care and Use of Laboratory Animals. Washington, DC: Government Printing Office; 1985. NIH publication 86-23.
14. Segars WP, Tsui BMW, Frey EC, Johnson GA, Berr SS. Development of a 4-D digital mouse phantom for molecular imaging research. Mol Imaging Biol. 2004;6:149-159.
15. Marshall D, Pedley RB, Melton RG, Boden JA, Boden R, Begent RH. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab9)2 fragments of an anti-tumor antibody. Br J Cancer. 1995;71:18-24.
16. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505-515.
17. Patel S, Stein R, Ong GL, Goldenberg DM, Mattes MJ. Enhancement of tumorto-nontumor localization ratios by hepatocyte-directed blood clearance of antibodies labeled with certain residualizing radiolabels. J Nucl Med. 1999;40: 1392-1401.
18. Ogawara K, Yoshida M, Higaki K, et al. Hepatic uptake of polystyrene microspheres in rats: effect of particle size on intrahepatic distribution. J Control Release. 1999;59:15-22.
19. Staud F, Nishikawa M, Takakura Y, Hashida M. Liver uptake and hepato-biliary transfer of galactosylated proteins in rats are determined by the extent of galactosylation. Biochim Biophys Acta. 1999;1427:183-192.
20. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802-1807.
21. Lewis MR, Wang M, Axworthy DB, et al. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med. 2003;44:1284-1292.
22. McBride WJ, Zanzonico P, Sharkey RM, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med. 2006;47: 1678-1688.
23. Moosmayer D, Berndorff D, Chang C-H, et al. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin Cancer Res. 2006;12:5587-5595.
24. 177Lu. Bioconjug Chem. 2006;17:485-492.
25. Graves SS, Dearstyne E, Lin Y, et al. Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res. 2003;9:3712-3721.
26. 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl Med Biol. 2004;31:213-223.
27. Pizzarello DJ, Witcofski RL. Medical Radiation Biology. 2nd ed. Philadelphia, PA: Lea and Febiger; 1982:151.
28. Chatal JF, Davodeau F, Cherel M, Barbet J. Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. J Cancer Res Ther. 2009;5(suppl):S36-S40.
29. Sharkey RM, Karacay H, Liywin S, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 2008;68:5282-5290.